209 related articles for article (PubMed ID: 8701851)
1. Effect of parenteral d-sotalol on transvenous atrial defibrillation threshold in a canine model of atrial fibrillation.
Iskos D; Lurie KG; Adler SW; Shultz JJ; Coffeen PR; Mulligan KA; Benditt DG
Am Heart J; 1996 Jul; 132(1 Pt 1):116-9. PubMed ID: 8701851
[TBL] [Abstract][Full Text] [Related]
2. Effect of electrode position on outcome of low-energy intracardiac cardioversion of atrial fibrillation.
Alt E; Schmitt C; Ammer R; Plewan A; Evans F; Pasquantonio J; Ideker T; Lehmann G; Pütter K; Schömig A
Am J Cardiol; 1997 Mar; 79(5):621-5. PubMed ID: 9068520
[TBL] [Abstract][Full Text] [Related]
3. Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Heisel A; Jung J; Fries R; Stopp M; Sen S; Schieffer H; Ozbek C
Pacing Clin Electrophysiol; 1997 Jan; 20(1 Pt 1):65-71. PubMed ID: 9121973
[TBL] [Abstract][Full Text] [Related]
4. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
Lau CP; Lok NS
Pacing Clin Electrophysiol; 1997 Oct; 20(10 Pt 1):2442-52. PubMed ID: 9358486
[TBL] [Abstract][Full Text] [Related]
5. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chronic atrial fibrillation in humans: assessment of the electrophysiological effects by biatrial basket electrodes.
Lai LP; Lin JL; Lien WP; Tseng YZ; Huang SK
J Am Coll Cardiol; 2000 May; 35(6):1434-41. PubMed ID: 10807444
[TBL] [Abstract][Full Text] [Related]
6. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial.
Singh SN; Tang XC; Reda D; Singh BN
Heart Rhythm; 2009 Feb; 6(2):152-5. PubMed ID: 19187902
[TBL] [Abstract][Full Text] [Related]
7. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.
Boriani G; Biffi M; Capucci A; Bronzetti G; Ayers GM; Zannoli R; Branzi A; Magnani B
J Am Coll Cardiol; 1999 Feb; 33(2):333-41. PubMed ID: 9973012
[TBL] [Abstract][Full Text] [Related]
8. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock.
Janardhan AH; Gutbrod SR; Li W; Lang D; Schuessler RB; Efimov IR
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):40-8. PubMed ID: 24076284
[TBL] [Abstract][Full Text] [Related]
9. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.
Tse HF; Lau CP; Ayers GM
Heart; 1999 Sep; 82(3):319-24. PubMed ID: 10455082
[TBL] [Abstract][Full Text] [Related]
10. Facilitating internal cardioversion of chronic atrial fibrillation with ibutilide--predictors of atrial defibrillation-threshold decrease.
Efremidis M; Sideris A; Batra R; Manolatos D; Xidonas S; Kardara D; Ekonomou D; Evagelou D; Filippatos G; Kardaras F
Med Sci Monit; 2004 Jun; 10(6):CR258-63. PubMed ID: 15173670
[TBL] [Abstract][Full Text] [Related]
11. Hybrid therapy of atrial fibrillation.
Santini M; Pignalberi C; Ricci R; Calò L
Ital Heart J; 2002 Oct; 3(10):571-8. PubMed ID: 12478814
[TBL] [Abstract][Full Text] [Related]
12. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock.
Li W; Janardhan AH; Fedorov VV; Sha Q; Schuessler RB; Efimov IR
Circ Arrhythm Electrophysiol; 2011 Dec; 4(6):917-25. PubMed ID: 21980076
[TBL] [Abstract][Full Text] [Related]
13. Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation.
Decloedt A; Broux B; De Clercq D; Deprez P; Van Steenkiste G; Vera L; Ven S; van Loon G
J Vet Intern Med; 2018 Mar; 32(2):815-821. PubMed ID: 29460446
[TBL] [Abstract][Full Text] [Related]
14. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Wong CK; White HD; Wilcox RG; Criger DA; Califf RM; Topol EJ; Ohman EM;
Heart; 2002 Oct; 88(4):357-62. PubMed ID: 12231591
[TBL] [Abstract][Full Text] [Related]
15. Clinical shock tolerability and effect of different right atrial electrode locations on efficacy of low energy human transvenous atrial defibrillation using an implantable lead system.
Lok NS; Lau CP; Tse HF; Ayers GM
J Am Coll Cardiol; 1997 Nov; 30(5):1324-30. PubMed ID: 9350935
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic performances in patients treated with sotalol after electrical cardioversion of atrial fibrillation.
Dan GA; Gonţa A
Rom J Intern Med; 1997; 35(1-4):19-27. PubMed ID: 9562649
[TBL] [Abstract][Full Text] [Related]
17. Initial clinical experience with an implantable human atrial defibrillator.
Lau CP; Tse HF; Lok NS; Lee KL; Ho DS; Sopher M; Murgatroyd F; Camm AJ
Pacing Clin Electrophysiol; 1997 Jan; 20(1 Pt 2):220-5. PubMed ID: 9121994
[TBL] [Abstract][Full Text] [Related]
18. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
[TBL] [Abstract][Full Text] [Related]
19. Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation.
Boriani G; Valzania C; Biffi M; Corazza I; Camanini C; Martignani C; Bacchi L; Zannoli R; Branzi A
Int J Cardiol; 2004 Jun; 95(2-3):245-50. PubMed ID: 15193827
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation.
Tse HF; Lau CP
J Am Coll Cardiol; 2002 Dec; 40(12):2150-5. PubMed ID: 12505228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
